Wedbush Maintains Outperform on Arcus Biosciences, Lowers Price Target to $45
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and lowers the price target from $49 to $45.
Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and lowers the price target from $49 to $45.